REG - Genus - Half Year Trading Update – Ahead of expectations

GenusAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260116:nRSP1316Pa&default-theme=true

RNS Number : 1316P  Genus PLC  16 January 2026

16 January 2026

Genus plc ("Genus" or the "Group")

Half Year Trading Update - Ahead of expectations

Genus (LSE: GNS), a leading global animal genetics company, publishes the
following unaudited trading update for the six months ended 31 December 2025
("H1 FY26").

Genus performed strongly in H1 FY26 and the Board expects to report first half
Group adjusted profit before tax (excluding the BCA milestone payment(1)
referenced below) of approximately £50m in actual currency, which is ahead of
our expectations. Including the BCA milestone payment, first half Group
adjusted profit before tax is expected to be approximately £55.6m in actual
currency.

Following the Group's AGM trading update in November 2025, PIC trading
continued to be strong and ABS traded as expected. The Board now expects Group
FY26 adjusted profit before tax (excluding the BCA milestone payment(1)) to be
moderately above the top-end of current market expectations(2).

On 4 September 2025, Genus announced the accelerated formation of its porcine
joint venture in China(3). The Group is pleased to confirm that formation of
the joint venture received regulatory approval from SASAC(4) in December 2025,
which has also triggered the final $7.5m (c. £5.6m) milestone payment from
BCA to Genus. Genus now expects formation of the Chinese porcine joint venture
and receipt of the milestone cash payment in its fiscal third quarter.

Genus will announce its interim results for the six month period from 1 July
2025 to 31 December 2025 on 26 February 2026.

For further information please contact:

Genus plc      Tel: +44 (0)1256 345 970

Jorgen Kokke, Chief Executive Officer

Andy Russell, Chief Financial Officer

Anand Date, Investor Relations & Sustainability Director

Burson Buchanan    Tel: +44 (0)207 466 5000

Charles Ryland; Mark Court; Toto Berger; Jamie Hooper

About Genus

Genus is a world-leading animal genetics company. Genus creates advances to
animal breeding and genetic improvement by applying biotechnology and sells
added value products for livestock farming and food producers. Its technology
is applicable across livestock species and is currently commercialised by
Genus in the dairy, beef and pork food production sectors.

Genus's worldwide sales are made in over seventy-five countries under the
trademarks 'ABS' (dairy and beef cattle) and 'PIC' (pigs) and comprise semen,
embryos and breeding animals with superior genetics to those animals currently
in farms. Genus's customers' animals produce offspring with greater production
efficiency, and quality, and use these to supply the global dairy and meat
supply chains.

The Group's competitive edge has been created from the ownership and control
of proprietary lines of breeding animals, the biotechnology used to improve
them and its global supply chain, technical service and sales and distribution
network. The PRRS(5) Resistant Pig is a market leading innovation in gene
editing which Genus is looking to commercialise in the porcine industry once
further regulatory approvals are obtained.

With headquarters in Basingstoke, United Kingdom, Genus companies operate in
over twenty-five countries on six continents, with research laboratories
located in Madison, Wisconsin, USA.

Footnotes

(1) Group adjusted profit before tax excludes the PRP-related milestone
payment from BCA triggered by receipt of regulatory approval from SASAC(4) and
the financial impact from the planned formation of the Group's porcine joint
venture in China

(2) The company compiled consensus estimate range for Group FY26 actual
currency adjusted profit before tax is £82.7m to £85.0m with an average
midpoint of £83.6m, and is based upon 9 analyst estimates

(3) Accelerated Chinese porcine joint venture formation
(https://genus2024eutfm.q4web.com/news/news-details/2025/Accelerated-Chinese-porcine-JV-formation/default.aspx)

(4) China's State-owned Assets Supervision and Administration Commission of
the State Council ("SASAC")

(5) PRRS (Porcine Reproductive and Respiratory Syndrome) Resistant Pig ("PRP")

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTSFIFWIEMSEFF



            Copyright 2019 Regulatory News Service, all rights reserved